Femasys inc. advances commercial readiness with appointment of richard spector to new position of chief commercial officer

-- seasoned sales and marketing executive with 25 years of experience leading public and private healthcare companies throughout various stages of commercialization will lead commercial launch of femaseed -- atlanta, feb. 06, 2024 (globe newswire) -- femasys inc. (nasdaq: femy), a biomedical company focused on meeting significant unmet needs for women worldwide with a broad portfolio of in-office, accessible solutions, including a lead, late-clinical stage product candidate and innovative therapeutic and diagnostic products, today announced the appointment of richard spector to chief commercial officer (cco), effective february 2024. mr. spector has 25 years of experience spanning a continuum of commercial stages at both public and private medical device and biopharmaceutical companies.
FEMY Ratings Summary
FEMY Quant Ranking